STOCKHOLM, December 13, 2011 /PRNewswire/ -- Pharmalink AB, today announces it has gained an exclusive global license to Archimedes Pharma Ltd.'s TARGIT® drug delivery technology for use in its lead ...
A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer. I-SPY 2 ...
Although breast-conserving therapy has long been vindicated, all patients still receive 'radical' whole-breast radiotherapy. Over the last decade, we have been questioning the concept of 'standard' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results